Warning: The NCBI web site requires JavaScript to function. more...
Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina.
Rubinstein A, García Martí S, Souto A, Ferrante D, Augustovski F.
Cost Eff Resour Alloc. 2009 May 6;7:10.
Related citations
Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY, Ko SK, Liew D.
Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8.
Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach.
Jackson R.
J Hum Hypertens. 1998 Sep;12(9):607-13. Review.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
The cost-effectiveness of interventions designed to reduce sodium intake.
Wang G, Labarthe D.
J Hypertens. 2011 Sep;29(9):1693-9. Review.
Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.
Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB.
Lancet. 2003 Mar 1;361(9359):717-25. Erratum in: Lancet. 2005 Jul 16-22;366(9481):204.
The global impact of noncommunicable diseases: estimates and projections.
Manton KG.
World Health Stat Q. 1988;41(3-4):255-66.
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D, Park HJ, Ko SK.
Clin Ther. 2009 Oct;31(10):2189-203; discussion 2150-1.
A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.
Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.
Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
Flynn MA, McNeil DA, Maloff B, Mutasingwa D, Wu M, Ford C, Tough SC.
Obes Rev. 2006 Feb;7 Suppl 1:7-66. Review.
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.
The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.
Health Technol Assess. 2006 Sep;10(32):iii-iv, ix-xii, 1-93.
Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
Bertram MY, Lim SS, Wallace AL, Vos T.
Tob Control. 2007 Aug;16(4):255-60.
Screening for type 2 diabetes: literature review and economic modelling.
Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A.
Health Technol Assess. 2007 May;11(17):iii-iv, ix-xi, 1-125. Review.
Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence.
Daviglus ML, Lloyd-Jones DM, Pirzada A.
Am J Cardiovasc Drugs. 2006;6(2):87-101. Review.
Prevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy.
Bovet P, Shamlaye C, Gabriel A, Riesen W, Paccaud F.
BMC Public Health. 2006 Jan 19;6:9.
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
Health Technol Assess. 2001;5(32):1-195. Review.
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.
Johnson WD, Diaz RM, Flanders WD, Goodman M, Hill AN, Holtgrave D, Malow R, McClellan WM.
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. Review.
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on